Out of frame peptides from BCR/ABL alternative splicing are immunogenic in HLA A2.1 transgenic mice

C. Casnici, G. Volpe, D. Lattuada, K. Crotta, M. Kuka, C. Panuzzo, C. Mastrotto, G. Tonon, V. M. Fazio, G. Saglio, O. Marelli

Research output: Contribution to journalArticlepeer-review

Abstract

New, potentially tumor-specific antigens have been described in Bcr/Abl positive leukemias. Besides the main BCR/ABL hybrid fusion transcripts, a small number of transcripts derived from alternative splicing between BCR exons 1, 13, and 14 with ABL exons 4 and 5 have been identified. These variants are expressed in chronic myelogenous leukemia and acute lymphocytic leukemia patients. The transcriptional products were characterized at their C-terminus by a large amino acid portion derived from out of frame (OOF) reading of the ABL gene. This OOF peptide is expressed only in leukemic cells and has no homology with known human proteins. In order to study an in vivo model, three 39-amino acid peptides, each corresponding to a third of the whole human OOF peptide sequence, were tested for their capacity to elicit specific immune responses in HLA A2.1 transgenic mice. Peptides A and B, but not C, induced the production of specific antisera, while A and C induced the generation of specific cytotoxic T lymphocytes.

Original languageEnglish
Pages (from-to)61-67
Number of pages7
JournalCancer Letters
Volume276
Issue number1
DOIs
Publication statusPublished - Apr 8 2009

Keywords

  • BCR/ABL transcripts
  • Cancer vaccine
  • Chronic myelogenous leukemia
  • HLA A2.1 transgenic mice
  • Peptide vaccination

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Out of frame peptides from BCR/ABL alternative splicing are immunogenic in HLA A2.1 transgenic mice'. Together they form a unique fingerprint.

Cite this